Sanofi is a pharmaceutical company that produces a wide range of health care products including cancer drugs. Earlier, the company manufactured insulin, which is used by diabetics for smooth functioning of the blood sugar level. However, it was discovered that Sanofi’s Sanafenil was not working effectively and that it also contained harmful side effects, which made the public lose faith in the product. Sanofi then introduced a new type of insulin, which had a better impact on diabetes patients.
However, Sanofi has faced a lot of criticism for introducing this new insulin and it was found that it caused severe hair loss in many people even though they were on chemotherapy treatment.
The reason behind the lawsuit is that the contaminated insulin did not work properly and caused Sanofi’s researchers to suffer from serious health conditions. The contaminated insulin that was used in the clinical trials of Sanafenil caused the cells to multiply excessively and produced excessive hair loss in the laboratory animals.
Due to this, the scientists had to abandon the clinical trial of Sanafenil and all the data of the previous tests were lost. This was a major setback for the company and it was unable to come up with solutions to the problems faced by the scientists.
It is evident from the above-mentioned scenario that the case filed against Sanofi is not a simple one.
For starters, it is a well-established fact that Sanofi’s new breast cancer treatment called Cymilium caused serious hair loss in all the clinical trials conducted by the company. However, it is not clear as to why this occurred or how the scientists were unable to control the hair loss in all the patients.
A recent court hearing is currently underway and is expected to take some time to come up with a decision. Sanofi is also facing other lawsuits on its breast cancer treatment called Barmensen.